Correlation of HLA-Cw6 Positivity with Clinical Characteristics and Treatment Efficacy in Korean Patients with Psoriasis

So Mim Kim, Heera Lee, Eun-So Lee

Department of Dermatology, Ajou University School of Medicine, Suwon, Korea

Background: Psoriasis is a multifactorial, chronic immunological disease, in which a specific allele HLA-Cw6 is associated with various clinical manifestations. However, information regarding this genetic factor in Korean patients with psoriasis remains limited.

Objective: We aimed to explore the differences in clinical patterns and treatment responsiveness, depending on the expression of HLA-Cw6, in Korean patients with psoriasis.

Methods: We divided patients into two groups, namely HLA-Cw6-positive and HLA-Cw6-negative, based on the HLA-Cw6 allelic analysis using the single specific primer-polymerase chain reaction method. All clinical information regarding these patients was collected in a retrospective manner. Next, we evaluated the levels of serum Th17-related cytokines in 34 patients diagnosed with psoriasis using a multiplex immunoassay. Finally, we performed immunohistochemical staining of interleukin (IL)-22 and IL-31, as these cytokines showed the maximum differential expression between the HLA-Cw6 positive and negative groups.

Results: HLA-Cw6 positive and negative groups comprised of 13 and 21 patients, respectively. HLA-Cw6-positive group had more chance of having metabolic comorbidities (76.9% for HLA-Cw6-positive group; 28.6% for HLA-Cw6-negative group; p=0.002). Also, HLA-Cw6-positive group showed significantly higher treatment response (38.5% in positive group showed Psoriasis Area and Severity Index 90% improvement compared to 4.8% in the negative group; p=0.012). However, all Th17-related cytokines were not significantly different across the two groups. Furthermore, IL-22 and IL-31 immunohistochemical staining did not correlate with the serum cytokines levels.

Conclusion: HLA-Cw6 types can be associated with disease severity, comorbidities, and treatment responsiveness in Korean patients with psoriasis.

Keywords: Cytokine, HLA-C*06 antigen, Psoriasis

INTRODUCTION

Psoriasis is a multifactorial chronic immunological disease characterized by erythematous patches or plaques with silver-white scales. Environmental stimuli, such as trauma and infection, are believed to cause psoriasis in patients with genetic factors. Psoriasis can involve organs other than the skin, such as joints, and has recently been reported to be related to metabolic syndrome or cardiovascular diseases. Therefore, it is now recognized as a whole-body disease rather than a simple skin disease.

Psoriasis is usually divided into early-onset, which occurs before the age of 40 years, and late-onset, which occurs after the age of 40 years. It is thought to be a polygenic multifactorial disease that is linked to various genes, and HLA-Cw6 has been reported to be associated with early-onset psoriasis. A study reported that HLA-Cw6 was expressed in 85.3% of early-onset patients and 14.7% of late-onset patients. Some scholars have classified early-onset, frequent relapse, higher severity, and family history of psoriasis with HLA-Cw6 ex-
pression as type 1 psoriasis and late-onset, relatively good prognosis, and no family history with HLA Cw6 expression as type 2 psoriasis.

Also, HLA-Cw6 positivity is known to be related to stress, obesity, and guttate psoriasis. In addition, patients carrying the allele are more likely to have arm, leg, and trunk involvement, along with the Koebner phenomenon. Several studies involving Caucasian and Chinese patients have shown HLA-Cw6-positive patients to be more responsive to methotrexate and ustekinumab; HLA-Cw6 positivity also tends to be less frequent in high-need patients, who fail conventional therapy. However, not much had been reported previously about the status of HLA-Cw6 in Korean patients with psoriasis. Only Nam et al. reported the presence of Cw*0602 is related to the early onset age and family history.

Thus, we aimed to explore the differences in clinical patterns and treatment responsiveness depending on the expression of HLA-Cw6 in Korean patients with psoriasis.

MATERIALS AND METHODS

We evaluated the venous blood samples (5~10 ml) and lesion tissues collected from 34 patients who were diagnosed with psoriasis at their first visit to the Department of Dermatology, Ajou University Hospital, between May 2016 and March 2019. The specimens were stored at the Human Genome Resource Center (Ajou University Hospital Biobank). The patients aged more than 20 years at the time of their first visit were enrolled for the study, and those with any systemic treatment history, such as with methotrexate, cyclosporine, biologics, and narrow-band ultraviolet B (NBUVB), 6 months before the initial visit, were excluded. Clinical information of all patients, such as sex, age, disease onset age, disease duration, history of smoking and drinking, body mass index (BMI), family history of psoriasis, metabolic comorbidities, accompanying pruritus, psoriatic arthritis, nail involvement, and treatment responsiveness using PASI score improvement (initial PASI score vs. PASI score after 6 months). PASI 50 meant 50% reduction, PASI 75 implied 75% reduction, and PASI 90 indicated 90% decrease of PASI scores compared to each initial PASI score after 24 weeks. Descriptive analyses, including the chi-squared test or Fisher’s exact test for categorical data and the two-sample t-test or Mann–Whitney U test for numerical data, were performed to evaluate the statistical significance of demographic data.

Also, the serum cytokine levels were measured by a multiplex immunoassay (Milliplex MAP, Millipore Corporation, Burlington, MA, USA). We particularly evaluated the initial levels of Th17-related cytokines (interleukin IL-17A, IL-17F, IL-21, IL-22, IL-23, tumor necrosis factor TNF-α, TNF-β, IL-6, IL-1β, IL-12, IL-27, interferon IFN-γ, IL-4, IL-5, IL-13, IL-25, IL-10, IL-28A, macrophage inflammatory protein-3 alpha MIP3A), granulocyte monocyte-colony stimulating factor GM-CSF, IL-15, IL-9, IL-33, IL-2, and IL-31. Differences in cytokine levels between HLA-Cw6 positive and negative groups were analyzed using the Mann–Whitney U test to compare the median value of the data, and the range was also presented. The result was considered statistically significant when the two-tailed p-value was <0.05. Statistical analyses were performed using SPSS Statistics 21.0 for Windows (IBM Corp., Armonk, NY, USA). Next, we performed immunohis-
tochemical staining for IL-22 and IL-31, the two cytokines that showed maximum differential expression between the two groups, to evaluate whether a correlation existed between serum cytokine levels and tissue cytokine expressions. Paraffin-embedded tissue sections of 3-μm thickness were processed for immunohistochemistry. The following primary antibodies were used: IL-22 (1:500; Abcam, Cambridge, MA, USA) and IL-31 (1:100, NBP2-80396; Novus, Centennial, CO, USA). Then, the degree of immunohistochemical staining was evaluated using ordinal classification (0, negative; 1, weak; 2, moderate; 3, strong).

This study protocol was approved by the Ajou Institutional Review Board (IRB No.: AJIRB-BMR-MDB-15-341) prior to study commencement. According to Helsinki ethical principles, written informed consents were obtained from all subjects before their enrollment in the study.

RESULTS

The patients underwent HLA-Cw6 genotype analysis were divided into two groups; 13 patients in HLA-Cw6-positive group and 21 patients in HLA-Cw6-negative group. Demographic and clinical characteristics of the study population are presented in Table 1. The mean age at initial visit was 43.69 years (standard deviation, 11.28 years) in the HLA-Cw6-positive group, and 47.43±13.09 years in HLA-Cw6-negative group. The onset age was less than 40 years in 84.6% of the patients in the HLA-Cw6-positive group and in 52.4% of the patients in the HLA-Cw6-negative group. Approximately 53.8% of the patients in the HLA-Cw6-positive group and 28.6% in the HLA-Cw6-negative group had high BMI (>25 kg/m²); 23.1% of the HLA-Cw6-positive group and 14.3% of the HLA-Cw6-negative group had a family history of psoriasis. Approximately 53.8% of HLA-Cw6-positive patients had accompanying pruritus while 23.8% of the HLA-Cw6-negative group had pruritus. Less than half had accompanying psoriatic arthritis in both groups (30.8% in the positive group and 23.8% in the negative group) along with nail involvement (30.8% of the positive group and 42.9% of the negative group). Likewise, those two groups showed no statistically significant discrepancy, except for metabolic comorbidities. The HLA-Cw6-positive group had more chance of having metabolic comorbidities, such as hypertension, diabetes, dyslipidemia, and cardiovascular disease (76.9% for the positive group and

| Characteristic          | HLA-Cw6 positive (n=13) | HLA-Cw6 negative (n=21) | p-value |
|-------------------------|-------------------------|--------------------------|---------|
| Sex                     |                         |                          | 0.152   |
| Male                    | 10 (76.9)               | 11 (52.4)                |         |
| Female                  | 3 (23.1)                | 10 (47.6)                |         |
| Age (yr)                | 43.69±11.28             | 47.43±13.09              |         |
| Onset age               |                         |                          | 0.056   |
| Early (<40 yr)          | 11 (84.6)               | 11 (52.4)                |         |
| Late (≥40 yr)           | 2 (15.4)                | 10 (47.6)                |         |
| Duration                |                         |                          | 0.643   |
| Short (<10 yr)          | 6 (46.2)                | 8 (38.1)                 |         |
| Prolonged (≥10 yr)      | 7 (53.8)                | 13 (61.9)                |         |
| Smoking                 |                         |                          | 0.456   |
| Non-smoker              | 9 (69.2)                | 11 (52.4)                |         |
| Smoker or ex-smoker     | 4 (30.8)                | 10 (47.6)                |         |
| Alcohol                 |                         |                          | 0.721   |
| Non-drinker             | 5 (38.5)                | 11 (52.4)                |         |
| Drinker or ex-drinker   | 8 (61.5)                | 10 (47.6)                |         |
| BMI                     |                         |                          | 0.094   |
| <18.5 kg/m²             | 0 (0.0)                 | 2 (9.5)                  |         |
| 18.5~25 kg/m²           | 6 (46.2)                | 13 (61.9)                |         |
| >25 kg/m²               | 7 (53.8)                | 6 (28.6)                 |         |
| Family history          |                         |                          | 0.513   |
| Yes                     | 3 (23.1)                | 3 (14.3)                 |         |
| No                      | 10 (76.9)               | 18 (85.7)                |         |
| Initial PASI            |                         |                          | 0.724   |
| <10                     | 6 (46.2)                | 11 (55.4)                |         |
| ≥10                     | 7 (53.8)                | 10 (47.6)                |         |
| Initial BSA             |                         |                          | 0.891   |
| <10%                    | 4 (30.8)                | 6 (28.6)                 |         |
| ≥10%                    | 9 (69.2)                | 15 (71.4)                |         |
| Metabolic comorbidities |                         |                          | 0.002   |
| Yes                     | 10 (76.9)               | 6 (28.6)                 |         |
| No                      | 3 (23.1)                | 15 (71.4)                |         |
| Pruritus                |                         |                          | 0.089   |
| Yes                     | 7 (53.8)                | 5 (23.8)                 |         |
| No                      | 6 (46.2)                | 16 (76.2)                |         |
| Psoriatic arthritis     |                         |                          | 0.655   |
| Yes                     | 4 (30.8)                | 5 (23.8)                 |         |
| No                      | 9 (69.2)                | 16 (76.2)                |         |
28.6% for the negative group).

In Table 2, the frequency of metabolic comorbidities is shown in both groups: 23.1% of the HLA-Cw6-positive group and 23.8% of the HLA-Cw6-negative group had hypertension, 30.8% of the HLA-Cw6-positive patients and 9.5% of the HLA-Cw6-negative patients had diabetes mellitus and dyslipidemia, and 7.7% of the HLA-Cw6-positive patients and 9.5% of the HLA-Cw6-negative patients had accompanying cardiovascular diseases.

The treatment responsiveness to the conventional systemic therapy such as methotrexate, cyclosporine and NBUVB of both groups are listed in Table 3 and shown in Fig. 1. All the patients received conventional therapy at least a month, however the dosage and the duration varied according to their severity. The HLA-Cw6-positive group showed a significantly higher PASI index (90% improvement over negative group; *p*=0.012).

The serum Th17-related cytokine levels in patients with psoriasis were assessed with respect to each HLA-Cw6 type shown in Table 4 and in Fig. 2. In general, HLA-Cw6-positive group showed tendency of higher levels of cytokines as seen in Fig. 2. IL-13 and IL-2 levels were found to be higher in the HLA-Cw6-negative group than in the HLA-Cw6-positive group; the levels of the other cytokines, such as IL-17F, MPIP3A, IL-15, IL-22, IL-1β, IL-33, IL-4, IL-23, IL-6, IL-25, IL-27, IL-31, TNF-α, TNF-β, and IL-28A were far higher in the HLA-Cw6-positive group. However, the levels were not significantly different between the two groups.

Even though there were no significantly different levels of serum cytokines, IL-22 and IL-31 showed relatively broad differences between HLA-Cw6 positive and negative groups. However, in the tissue IL-22 and IL-31 immunohistochemical staining conducted accordingly showed no correlation with the serum cytokine levels (relative expression level of IL-22 in dermis, 1.21 for positive group and 1.00 for negative group; *p*=0.756; relative expression level of IL-31 in dermis, 0.44 for positive group and 0.71 for negative group).

Table 1. Continued

| Characteristic | HLA-Cw6 positive (n=13) | HLA-Cw6 negative (n=21) | p-value |
|----------------|------------------------|-------------------------|---------|
| Nail involvement |                         |                         | 0.481   |
| Yes | 4 (30.8) | 9 (42.9) |         |
| No | 9 (69.2) | 12 (57.1) |         |
| Treatment modalities |                         |                         | 0.481   |
| MTX | 11 (84.6) | 14 (66.7) | 0.628   |
| CsA | 4 (30.8) | 6 (28.6) | 0.892   |
| NBUVB | 5 (38.5) | 7 (33.3) | 0.523   |

Values are presented as number (%) or mean±standard deviation. BMI: body index mass, PASI: Psoriatic Area Severity Index, BSA: body surface area, MTX: methotrexate, CsA: cyclosporine, NBUVB: narrow-band ultraviolet B.

Table 2. Metabolic comorbidities

| Comorbidity | HLA-Cw6 positive (n=13) | HLA-Cw6 negative (n=21) | p-value |
|-------------|------------------------|-------------------------|---------|
| Hypertension | 3 (23.1) | 5 (23.8) | 0.962   |
| Diabetes mellitus | 4 (30.8) | 2 (9.5) | 0.121   |
| Dyslipidemia | 4 (30.8) | 2 (9.5) | 0.121   |
| Cardiovascular disease | 1 (7.7) | 2 (9.5) | 0.860   |

Values are presented as number (%).

Table 3. Assessment of PASI score response after 24 weeks

| PASI improvement | HLA-Cw6 positive (n=13) | HLA-Cw6 negative (n=21) | p-value |
|------------------|------------------------|-------------------------|---------|
| After 24 wk      |                        |                         |         |
| PASI 50% improvement | 8 (61.5) | 11 (52.4) | 0.601   |
| PASI 75% improvement | 7 (53.8) | 5 (23.8) | 0.075   |
| PASI 90% improvement | 5 (38.5) | 1 (4.8) | 0.012   |

Values are presented as number (%). PASI: Psoriasis Area and Severity Index.

Fig. 1. PASI response after 24 weeks of treatment based on HLA-Cw6 type. After 24 weeks of treatment with methotrexate, cyclosporine, or narrow-band ultraviolet B, the probability of achieving PASI 50, 75, and 90 was high in the HLA-Cw6-positive group. Among them, the proportion of patients achieving PASI 90 differed statistically. PASI: Psoriasis Area and Severity Index. *Statistical significance (*p*<0.05).
DISCUSSION

Overall, this study was able to achieve results similar to those reported by previous studies. HLA-Cw6-positivity was shown to be associated with early-onset age, more chance of having metabolic diseases, and significantly higher treatment responses. Especially in this study, higher PASI 50, 75, and 90 were achieved in the HLA-Cw6-positive group after conventional systemic therapy with methotrexate, cyclosporine and NBUVB irradiation; the treatment response was confirmed by evaluating PASI 24 weeks after treatment initiation. This is in line with the better effect of HLA-Cw6-positive group in the methotrexate-treated patients in the other studies.

In addition to affecting the skin, psoriasis is well known to affect joints. Recently, it has been confirmed that more severe psoriasis is related with higher risk of developing metabolic and cardiovascular diseases, such as myocardial infarction, atherosclerosis, pulmonary thrombosis, stroke, hypertension, hyperlipidemia, obesity, and diabetes. Both obesity and psoriasis indicate an increase in C-reactive protein, IL-6, TNF-α, and leptin levels. This means that the two diseases are common systemic inflammatory diseases and this might explain the link between metabolic syndrome and psoriasis. The relevance of psoriasis and atherosclerosis can also be explained

Table 4. The serum cytokine levels in patients with psoriasis according to HLA-Cw6 types

| Serum cytokine | HLA-Cw6 type | p-value |
|---------------|--------------|---------|
|               | Positive (n=13) | Negative (n=21) | |
| IL-17F        | 4.74 (0.10~8.50) | 0.84 (0.01~31.32) | 0.246 |
| GM-CSF        | 34.32 (10.59~143.66) | 30.78 (2.76~151.11) | 0.727 |
| IFN-γ         | 5.53 (2.97~13.04) | 5.01 (2.40~20.78) | 0.807 |
| IL-10         | 0.27 (0.01~3.34) | 0.17 (0.01~27.03) | 0.972 |
| MIP3A         | 25.33 (0.55~73.20) | 19.96 (0.55~132.82) | 0.576 |
| IL-12P70      | 8.53 (1.74~34.30) | 7.09 (1.23~43.53) | 0.701 |
| IL-13         | 261.19 (16.39~677.43) | 346.13 (61.19~805.60) | 0.506 |
| IL-15         | 4.03 (0.66~14.76) | 2.31 (0.50~27.62) | 0.292 |
| IL-17A        | 4.57 (2.82~8.80) | 4.15 (1.60~25.98) | 0.972 |
| IL-22         | 31.06 (0.07~969.81) | 4.69 (0.00~828.65) | 0.050 |
| IL-9          | 0.58 (0.10~120.06) | 0.48 (0.04~120.06) | 0.889 |
| IL-1β         | 3.58 (1.66~5.61) | 2.77 (0.68~9.88) | 0.552 |
| IL-33         | 3.67 (0.03~74.81) | 0.39 (0.00~94.94) | 0.309 |
| IL-2          | 6.86 (4.17~19.42) | 7.37 (1.85~30.22) | 0.506 |
| IL-21         | 26.45 (0.10~81.58) | 23.23 (0.07~137.20) | 1.000 |
| IL-4          | 4.01 (0.20~399.17) | 2.12 (0.06~701.05) | 0.441 |
| IL-23         | 0.03 (0.00~3799.00) | 0.00 (0.00~7436.00) | 0.344 |
| IL-5          | 7.26 (1.75~20.33) | 5.97 (1.61~37.65) | 0.944 |
| IL-6          | 0.00 (0.00~97.02) | 0.00 (0.00~170.39) | 0.675 |
| IL-25         | 45.89 (13.97~177.42) | 28.69 (7.89~194.13) | 0.309 |
| IL-27         | 895.51 (249.49~1573.00) | 633.22 (59.41~1791.00) | 0.193 |
| IL-31         | 12.43 (2.12~166.60) | 5.76 (0.88~162.69) | 0.096 |
| TNF-α         | 37.40 (10.20~61.56) | 25.33 (7.39~68.60) | 0.148 |
| TNF-β         | 0.10 (0.01~246.35) | 0.01 (0.00~712.06) | 0.181 |
| IL-28A        | 0.55 (0.00~1983.00) | 0.00 (0.00~4053.00) | 0.529 |

Values are presented as median value (range). IL: interleukin, GM-CSF: granulocyte monocyte-colony stimulating factor, IFN: interferon, MIP3A: macrophage inflammatory protein-3 alpha, TNF: tumor necrosis factor.

positive group and 0.27 for negative group; p=0.877).

Values are presented as median value (range). IL: interleukin, GM-CSF: granulocyte monocyte-colony stimulating factor, IFN: interferon, MIP3A: macrophage inflammatory protein-3 alpha, TNF: tumor necrosis factor.
by chronic inflammatory reactions of skin and vascular tissues due to functional degradation of Treg cells and excessive activation of Th1 and Th17 cells. Other inflammatory diseases accompanying psoriasis include ulcerative colitis and Crohn’s disease, which are inflammatory bowel diseases; however, they have not been identified in this study group.

In the current study, there was no initial level of serum cytokine that showed a statistically significant difference between the groups divided based on HLA-Cw6 positivity. However, IL-22 and IL-31 showed relatively wide differences between HLA-Cw6 positive and negative group. IL-22 is a cytokine that is highly correlated with severity of the disease as it increases not only in psoriatic skin lesions but also in plasma samples of the patients. TNF blockers are associated with an early reduction in the expression of IL-22 and its target molecules, such as IL-20 and antimicrobial peptide β-defensin 2 (BD2), in psoriatic lesions. A previous study had reported a significant decrease in the IL-22 level in the IL-22 level in the group with the higher therapeutic response and suggested IL-22 as a responsive marker during treatment. In this study, we could not confirm the change in the IL-22 level, since the serum level after treatment was not measured; however, we could predict the possibility of a significant drop after treatment, since the initial level was high in the HLA-Cw6-positive group. We cannot still rule out the possibility of the initial high-level of IL-22 across the HLA-Cw6-positive patients being due to the higher PASI averages in the positive group, although they were not statistically significant. Based on the results of this study, we recommended that further studies should be performed to evaluate the association of HLA-Cw6 positivity with IL-22 expression. Moreover, targeting the IL-22-IL-22R system would be a more specific therapeutic intervention for HLA-Cw6-positive patients, since it is not anticipated to induce major side effects, especially since immune cells are not responsive to IL-22.

Besides IL-22, another cytokine that showed a wide difference was IL-31. IL-31 is known primarily to be associated with an itching sensation in inflammatory skin disorders such as atopic dermatitis and psoriasis. Recent investigations have reported serum IL-31 levels to be significantly elevated in psoriasis and chronic itch associated with psoriatic skin, owing to increased transcription of IL-31. Narbutt et al. further showed IL-31 serum levels to be significantly reduced after narrowband UVB phototherapy, coinciding with a substantial reduction in itching sensation in these patients. In this study, the p-value was 0.096, which was not statistically significant, although the HLA-Cw6-positive group indicated an IL-31 value higher than that in the HLA-Cw6-negative group. Following the same trend as the serum IL-31 level, patients who reported itching sensation at the time of treatment also showed higher in the HLA-Cw6-positive group (53.8%) than in the HLA-Cw6-negative group (23.8%). Thus, we were
not able to confirm the statistical significance of HLA-Cw6 positivity, although it was associated with itching sensation. Therefore, screening and management of itching would be important while treating HLA-Cw6-positive patients.

One of the limitations of this study is the small number of subjects. The rate of HLA-Cw6 positivity was low 5.66% in Koreans, which made it difficult to recruit positive patients. Disadvantage of this small number is that differences in drug responsiveness (methotrexate vs. cyclosporine) could not be identified separately through subgroup analysis. Moreover, it would have been better to reacquire serum 24 weeks after treatment to examine the change in cytokine levels, including the levels of IL-22 and IL-31. Moreover, immunohistochemical staining results may not have been accurate as some of the tissue samples were obtained several years ago. We hope to understand the relationship between these cytokines and HLA-Cw6, in depth, in future studies.

CONFLICTS OF INTEREST
The authors have nothing to disclose.

FUNDING SOURCE
This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HI16C0992).

DATA SHARING STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
So Min Kim, https://orcid.org/0000-0002-6066-5034
Heera Lee, https://orcid.org/0000-0002-5448-2274
Eun-So Lee, https://orcid.org/0000-0003-0232-7704

REFERENCES
1. Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and metabolic syndrome: a systematic review and meta-analysis of observational studies. J Am Acad Dermatol 2013;68:654-662.
2. Mehta NN, Azfar RS, Shin DB, Neumann AL, Troyel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2010;31:1000-1006.
3. Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol 2018;178:854-862.
4. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-456.
5. Theodorakopoulou E, Yu Z, Bundy C, Chularojanamontri L, Gittins M, Jameson LA, et al. Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. Br J Dermatol 2016;175:1038-1044.
6. Chiu HY, Wang TS, Chan CC, Cheng YP, Lin SJ, Tsai TF. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis. Br J Dermatol 2014;171:1181-1188.
7. Chiu HY, Huang PY, Lee SH, Hu CY, Chou CT, Chang YT, et al. HLA polymorphism among Chinese patients with chronic plaque psoriasis: subgroup analysis. Br J Dermatol 2012;166:288-297.
8. Zhou Y, Cai M, Sheng Y, Zhang X. A large-scale, stratified genetic analysis of the major histocompatibility complex region in early- and late-onset psoriasis in China. Ann Dermatol 2021;33:61-67.
9. Indhumathi S, Rajappa M, Chandrashekar L, Ananthanarayanan PH, Thappa DM, Negi VS. Pharmacogenetic markers to predict the clinical response to methotrexate in south Indian Tamil patients with psoriasis. Eur J Clin Pharmacol 2017;73:965-971.
10. Galluzzo M, Boca AN, Botti E, Potenza C, Malara G, Malagoli P, et al. IL12B (p40) gene polymorphisms contribute to ustekinumab response prediction in psoriasis. Dermatology 2016;232:230-236.
11. Talamonti M, Botti E, Galluzzo M, Teoli M, Spallone G, Bavetta M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol 2013;169:458-463.
12. Talamonti M, Galluzzo M, Chimenti S, Costanzo A. HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: outcome and long-term follow-up. J Am Acad Dermatol 2016;74:374-375.
13. Nam SH, Kim CW, Kim SS, Kim KH, Lee KW, Kim KJ. Correlations between HLA-Cw*0602 and clinical picture in Korean psoriatic patients. Korean J Dermatol 2001;39:183-189.
14. Talamonti M, Galluzzo M, van den Reek JM, de Jong EM, Lambert...
JLW, Malagoli P, et al. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients. Br J Dermatol 2017;177:489-496.

15. Liakou AI, Zouboulis CC. Links and risks associated with psoriasis and metabolic syndrome. Psoriasis (Auckl) 2015;5:125-128.

16. Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol 2011;20:544-549.

17. Whitlock SM, Enos CW, Armstrong AW, Gottlieb A, Langley RG, Lebwohl M, et al. Management of psoriasis in patients with inflammatory bowel disease: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol 2018;78:383-394.

18. Wolk K, Witte E, Wallace E, Docke WD, Kunz S, Asadullah K, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006;36:1309-1323.

19. Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 2014;13:21-38.

20. Zaba LC, Cardinale I, Gilleaudeau P, Sullivan-Whalen M, Suárez-Fariñas M, Fuentes-Duculan J, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-3194. Erratum in: J Exp Med 2008;205:1941.

21. Shimauchi T, Hirakawa S, Suzuki T, Yasuma A, Majima Y, Tatsuno K, et al. Serum interleukin-22 and vascular endothelial growth factor serve as sensitive biomarkers but not as predictors of therapeutic response to biologics in patients with psoriasis. J Dermatol 2013;40:805-812. Erratum in: J Dermatol 2013;40:856.

22. Gibbs BF, Patsinakidis N, Raap U. Role of the pruritic cytokine IL-31 in autoimmune skin diseases. Front Immunol 2019;10:1383.

23. Narbutt J, Olejniczak I, Sobolewska-Sztychń D, Sysa-Jedrzejowska A, Slowik Kwiatkowska I, Hawro T, et al. Narrow band ultraviolet B irradiations cause alteration in interleukin-31 serum level in psoriatic patients. Arch Dermatol Res 2013;305:191-195.

24. Nattkemper LA, Tey HL, Valdes-Rodriguez R, Lee H, Mollanazar NK, Albornoz C, et al. The genetics of chronic itch: gene expression in the skin of patients with atopic dermatitis and psoriasis with severe itch. J Invest Dermatol 2018;138:1311-1317.

25. Hwang SH, Oh H, Yang JH, Kwon O, Shin E. Distribution of HLA-A, B, C allele and haplotype frequencies in Koreans. Korean J Lab Med 2004;24:396-404.